Literature DB >> 84042

Immunodeterminant specificity of human immunity to type III group B streptococcus.

D L Kasper, C J Baker, R S Baltimore, J H Crabb, G Schiffman, H J Jennings.   

Abstract

The type III polysaccharides of group B Streptococcus in its native state chemically consists of glucose, galactose, glucosamine, and sialic acid. The core of this polysaccharide lacks sialic acid and precipitates with type III antiserum to give a partial identity with the precipitate between the native antigen and this serum. The core determinant is immunochemically similar to the capsular polysaccharide of type XIV Streptococcus pneumoniae, while the native type III group B streptococcal polysaccharide does not cross-react with type XIV pneumococcal antiserum. In human sera, it is antibody directed to the native antigen which correlates very highly with opsonic immunity (r = 0.94) while a poorer correlation exists between antibody to the core antigen and opsonins (r = 0.51 P less than 0.001). In natural infections, as association exists between low levels of maternal antibody to the native antigen and risk of disease in the infant. This association is not true for antibody to the core structure, where both infected infants and their mothers have much higher levels of antibody to the core than the native antigens. Infected infants are also more likely to respond to infection by developing antibody to the native antigen. Immunization of 12 adults with multivalent pneumococcal polysaccharide induced significantly better antibody response to the core antigen than to the native, and this vaccine induced opsonic activity in only one recipient. Immunization of adults with type III group B streptococcal antigens induced antibody to the native determinant which correlated with opsonic activity. Therefore, it would appear that native group B streptococcal polysaccharides will provide the best candidate antigens for immunization.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 84042      PMCID: PMC2184812          DOI: 10.1084/jem.149.2.327

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease.

Authors:  G R Siber; S A Weitzman; A C Aisenberg; H J Weinstein; G Schiffman
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

2.  Structural studies on the specific type-14 pneumococcal polysaccharide.

Authors:  B Lindberg; J Lönngren; D A Powell
Journal:  Carbohydr Res       Date:  1977-09       Impact factor: 2.104

3.  Antibody response to capsular polysaccharide vaccine of Streptococcus pneumoniae in patients with nephrotic syndrome.

Authors:  S M Fikrig; G Schiffman; J C Phillipp; D I Moel
Journal:  J Infect Dis       Date:  1978-06       Impact factor: 5.226

4.  The isolation and some physiochemical and biologic properties of the type 3 antigen of group B streptococci.

Authors:  H Russell; N L Norcross
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

5.  Immunochemistry of purified polysaccharide type antigens of group B streptococcal types Ia, Ib, and Ic.

Authors:  H W Wilkinson
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

6.  Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci.

Authors:  R S Baltimore; D L Kasper; C J Baker; D K Goroff
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

7.  Immunogenicity of polysaccharides from type III, group B Streptococcus.

Authors:  C J Baker; M S Edwards; D L Kasper
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

8.  Detection of group B streptococcal antibodies in human sera by radioimmunoassay: concentrations of type-specific antibodies in sera of adults and infants infected with group B streptococci.

Authors:  H W Wilkinson
Journal:  J Clin Microbiol       Date:  1978-02       Impact factor: 5.948

9.  Immune response after splenectomy.

Authors:  J L Sullivan; H D Ochs; G Schiffman; M R Hammerschlag; J Miser; E Vichinsky; R J Wedgwood
Journal:  Lancet       Date:  1978-01-28       Impact factor: 79.321

10.  Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus.

Authors:  C J Baker; D L Kasper; A Paredes; S Alpert; W M McCormack; D Goroff
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  36 in total

1.  Measurement of human antibodies to type III group B Streptococcus.

Authors:  D L Kasper; M R Wessels; H K Guttormsen; L C Paoletti; M S Edwards; C J Baker
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence.

Authors:  C E Rubens; M R Wessels; L M Heggen; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 3.  Interaction of neonatal phagocytes with group B streptococcus: recognition and response.

Authors:  Philipp Henneke; Reinhard Berner
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  The immune response to group B streptococcus type III capsular polysaccharide is directed to the -Glc-GlcNAc-Gal- backbone epitope.

Authors:  Dodi Safari; Huberta A T Dekker; Ger T Rijkers; Arie van der Ende; Johannis P Kamerling; Harm Snippe
Journal:  Glycoconj J       Date:  2011-10-08       Impact factor: 2.916

5.  Dendritic cell-derived exosomes express a Streptococcus pneumoniae capsular polysaccharide type 14 cross-reactive antigen that induces protective immunoglobulin responses against pneumococcal infection in mice.

Authors:  Jesus Colino; Clifford M Snapper
Journal:  Infect Immun       Date:  2006-10-16       Impact factor: 3.441

6.  Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.

Authors:  T Lagergard; J Shiloach; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

7.  Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci.

Authors:  B F Anthony; N F Concepcion; C A Wass; D C Heiner
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

8.  Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide.

Authors:  Filippo Carboni; Roberto Adamo; Monica Fabbrini; Riccardo De Ricco; Vittorio Cattaneo; Barbara Brogioni; Daniele Veggi; Vittoria Pinto; Irene Passalacqua; Davide Oldrini; Rino Rappuoli; Enrico Malito; Immaculada Y Ros Margarit; Francesco Berti
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

9.  Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.

Authors:  R Bhushan; B F Anthony; C E Frasch
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.

Authors:  M R Wessels; P Butko; M Ma; H B Warren; A L Lage; M C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.